Tissue concentration of systemically administered antineoplastic agents in human brain tumors

[1]  G. Gallia,et al.  Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme , 2010, Journal of Neuro-Oncology.

[2]  A. Palmer,et al.  Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds , 2010, Neurobiology of Disease.

[3]  B. Badie,et al.  The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation , 2009, Clinical Cancer Research.

[4]  H. Sarin.  Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors , 2009, Journal of Translational Medicine.

[5]  Colin M. Wilson,et al.  Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells , 2008, Journal of Translational Medicine.

[6]  David S. Miller,et al.  Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy , 2008, Pharmacological Reviews.

[7]  J. Blakeley.  Drug delivery to brain tumors , 2008, Current neurology and neuroscience reports.

[8]  A. Heerschap,et al.  Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization , 2008, Molecular Cancer Therapeutics.

[9]  Susan M. Chang,et al.  Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[10]  A. Nies.  The role of membrane transporters in drug delivery to brain tumors. , 2007, Cancer letters.

[11]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[12]  K. Hynynen,et al.  Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Frei,et al.  Gefitinib concentrations in human glioblastoma tissue , 2007, Journal of Neuro-Oncology.

[14]  A. Brandes,et al.  Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.

[15]  M. Desai,et al.  Randomized Study of Paclitaxel and Tamoxifen Deposition into Human Brain Tumors: Implications for the Treatment of Metastatic Brain Tumors , 2006, Clinical Cancer Research.

[16]  R. Bendayan,et al.  Multidrug Resistance-Associated Proteins: Expression and Function in the Central Nervous System , 2006, Pharmacological Reviews.

[17]  W. Yuh,et al.  Contrast-Enhanced Magnetic Resonance Imaging of Central Nervous System Tumors: Agents, Mechanisms, and Applications , 2006, Topics in magnetic resonance imaging : TMRI.

[18]  J. Gallo,et al.  In vivo microdialysis for PK and PD studies of anticancer drugs , 2005, The AAPS Journal.

[19]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[20]  N. Abbott.  Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. , 2004, Drug discovery today. Technologies.

[21]  David A Winkler,et al.  Modelling blood-brain barrier partitioning using Bayesian neural nets. , 2004, Journal of molecular graphics & modelling.

[22]  Iain Martin,et al.  Prediction of blood-brain barrier penetration: are we missing the point? , 2004, Drug discovery today.

[23]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[24]  Marco van Vulpen,et al.  Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). , 2002, Oncology reports.

[25]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[26]  J M Gallo,et al.  Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. , 2001, Cancer research.

[27]  S. Leenstra,et al.  High Concentration of Daunorubicin and Daunorubicinol in Human Malignant Astrocytomas after Systemic Administration of Liposomal Daunorubicin , 2001, Journal of Neuro-Oncology.

[28]  J. Beijnen,et al.  Penetration of Idarubicin into Malignant Brain Tumor Tissue , 1999, Journal of Neuro-Oncology.

[29]  Subhash C. Basak,et al.  Predicting Blood-Brain Transport of Drugs: A Computational Approach , 1996, Pharmaceutical Research.

[30]  M. Taphoorn,et al.  Paclitaxel (Taxol) concentrations in brain tumor tissue. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  T. Ohmoto,et al.  [Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumor and normal brain tissues]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[32]  M. Higashiyama,et al.  Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer , 1993, Journal of Neuro-Oncology.

[33]  M. Hariz,et al.  Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans. , 1993, British Journal of Cancer.

[34]  A. Hagenbeek,et al.  Management of relapse and survival in advanced stage Hodgkin's disease: the EORTC experience. , 1991, Annals of Oncology.

[35]  J. Miller,et al.  The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications. , 1990, Journal of neurosurgery.

[36]  D. Stewart,et al.  Penetration of teniposide (VM-26) into human intracerebral tumors , 1984, Journal of Neuro-Oncology.

[37]  R. Dedrick,et al.  Distributed model for drug delivery to CSF and brain tissue. , 1983, The American journal of physiology.

[38]  D. Groothuis,et al.  Brain tumors and the blood—brain barrier , 1982, Trends in Neurosciences.

[39]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[40]  U. Bickel,et al.  How to measure drug transport across the blood-brain barrier , 2011, NeuroRX.

[41]  Susan M. Chang,et al.  A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.

[42]  J. Olson,et al.  Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study , 2008, Journal of Neuro-Oncology.

[43]  C. Waters,et al.  Pharmacokinetic Considerations in the Treatment of CNS Tumours , 2006, Clinical pharmacokinetics.

[44]  R. M. Green,et al.  Human central nervous system and plasma pharmacology of mitoxantrone , 2004, Journal of Neuro-Oncology.

[45]  D. Stewart,et al.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors , 2004, Journal of Neuro-Oncology.

[46]  K. Sugiyama,et al.  Penetration of etoposide into human malignant brain tumors after intravenous and oral administration , 2004, Cancer Chemotherapy and Pharmacology.

[47]  Meindert Danhof,et al.  Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting , 2002, Clinical pharmacokinetics.

[48]  I. Whittle,et al.  Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin. , 1999, British journal of neurosurgery.

[49]  M. Zucchetti,et al.  Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin , 1999, Cancer Chemotherapy and Pharmacology.

[50]  I. Whittle,et al.  Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. , 1999, British journal of neurosurgery.

[51]  J. Beijnen,et al.  The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue , 1997, Cancer Chemotherapy and Pharmacology.

[52]  M. Zucchetti,et al.  Concentrations of VP16 and VM26 in human brain tumors. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.